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Shiga toxin-producing Escherichia coli is a principal source of regional outbreaks of bloody diarrhea and
hemolytic-uremic syndrome in the United States and worldwide. Primary bacterial virulence factors are Shiga
toxin types 1 and 2 (Stx1 and Stx2), and we performed parallel analyses of the pathophysiologies elicited by the
toxins in nonhuman primate models to identify shared and unique consequences of the toxemias. After a single
intravenous challenge with purified Stx1 or Stx2, baboons (Papio) developed thrombocytopenia, anemia, and
acute renal failure with loss of glomerular function, in a dose-dependent manner. Differences in the timing and
magnitude of physiologic responses were observed between the toxins. The animals were more sensitive to Stx2,
with mortality at lower doses, but Stx2-induced renal injury and mortality were delayed 2 to 3 days compared
to those after Stx1 challenge. Multiplex analyses of plasma inflammatory cytokines revealed similarities
(macrophage chemoattractant protein 1 [MCP-1] and tumor necrosis factor alpha [TNF-]) and differences
(interleukin-6 [IL-6] and granulocyte colony-stimulating factor [G-CSF]) elicited by the toxins with respect to
the mediator induced and timing of the responses. Neither toxin induced detectable levels of plasma TNF-.
To our knowledge, this is the first time that the in vivo consequences of the toxins have been compared in a
parallel and reproducible manner in nonhuman primates, and the data show similarities to patient observa-
tions. The availability of experimental nonhuman primate models for Stx toxemias provides a reproducible
platform for testing antitoxin compounds and immunotherapeutics with outcome criteria that have clinical
meaning.
Infection with Shiga toxin-producing Escherichia coli
(STEC) results in intestinal cramps and bloody diarrhea, fol-
lowed 5 to 12 days later in some patients by the development
of hemolytic-uremic syndrome (HUS) (16, 18). HUS is char-
acterized clinically by the triad of thrombocytopenia, hemolytic
microangiopathy, and renal injury and is the leading cause of
acute renal failure in otherwise healthy children in the United
States. An antibiotic regimen is not recommended, and treat-
ment options are limited to critical care support (47). Patients
with diarrhea-associated HUS can have long-term renal im-
pairment of varying severity, and approximately one-fourth of
patients have neurologic sequelae, including seizures, coma/
stupor, cortical blindness, ataxia, and paraplegia (10, 14).
The natural infection route is gastrointestinal, via contami-
nated food or water. The bacteria colonize the intestinal lu-
men, with most strains forming characteristic attaching-and-
effacing lesions, and the organisms may synthesize and release
one or more toxins that are primary virulence factors contrib-
uting to the clinical manifestations of HUS (19). The toxins are
AB5 holotoxins, referred to as Shiga toxins due to their func-
tional and structural similarities to Shiga toxin expressed by
Shigella dysenteriae serotype 1 (4). Shiga toxin type 1 (Stx1) is
essentially identical to the Shigella toxin (4), differing by one
amino acid, but shares only 58% amino acid identity with Shiga
toxin type 2 (Stx2). Stx1 and Stx2 have distinct spatial confor-
mations (8) and dissociation rates from receptor-lipid surfaces
(24). STEC strains may secrete one or both toxins and several
toxin variants, and clinical studies have demonstrated that
HUS is most often associated with the expression of Stx2 (3),
particularly following infection with E. coli O157:H7 strains
(12, 20). All Shiga toxins share a cellular intoxication mecha-
nism in which B subunits oligomerize into pentamers for
interaction with a cell surface globotriaosylceramide Gb3
(CD77) receptor. Following binding, holotoxins are internal-
ized via clathrin-dependent or clathrin-independent mecha-
nisms and undergo retrograde transport through the trans-
Golgi network and Golgi apparatus to reach the endoplasmic
reticulum (33, 46). During transport, the A subunit undergoes
limited proteolysis, and once in the endoplasmic reticulum, a
fragment of the A subunit translocates into the cytoplasm,
where its N-glycosidase activity inactivates the 28S rRNA com-
ponent of eukaryotic ribosomes to inhibit protein synthesis and
cause cell death (25, 43).
While Stx1 and Stx2 share many characteristics, they are not
identical and there is evidence that toxin-specific activities may
be clinically relevant. Both toxins are internalized after binding
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to Gb3, but the mechanisms of their intracellular trafficking
through polarized intestinal epithelial cells to reach the intes-
tinal endothelium are very different (15). Also, endothelial
sensitivities to Stx1 and Stx2 differ depending on the vascular
bed, with intestinal endothelium being more sensitive to the
Shiga toxins than saphenous vein endothelium (12), and glo-
merular endothelial cells are about 1,000 times more sensitive
to Stx2 than human umbilical vein endothelial cells (17). The
mechanisms for these differences are not completely under-
stood but may be related to receptor density, toxin effects on
endoplasmic reticulum stress responses and apoptosis (22, 41),
or local availability of sensitizing cytokines (5, 7, 11).
Most animal models show greater sensitivity to Stx2, includ-
ing murine, rabbit, and gnotobiotic piglet models, although
renal and neurologic micropathologies differ from those in
humans and between animal species (6, 9, 45). Earlier studies
with the baboon (Papio) model showed that a bolus infusion of
purified Stx1 induced intestinal injury, kidney glomerular in-
jury, microangiopathic anemia, thrombocytopenia, and neuro-
logic abnormalities similar to those in humans, suggesting that
the baboon represents a promising preclinical animal model
(44). A systemic inflammatory response was minimal after Stx1
challenge, but urinary tumor necrosis factor alpha (TNF-)
and interleukin-6 (IL-6) levels were consistent with local kid-
ney inflammatory responses. Baboons were also more sensitive
to Stx2 (38), but a direct comparison of the pathophysiologies
elicited by the two toxins was difficult because of differing
experimental designs. We sought to expand these earlier stud-
ies of baboons to identify similarities and differences elicited by
Stx1 and Stx2 under reproducible experimental conditions.
Given the clinical relevance of Stx2 production during STEC
infection in patients, we were particularly interested in re-
sponses after Stx2 challenge, for which few data are available
from the baboon model. We present the metabolic, physio-
logic, and inflammatory responses in baboons after intrave-
nous challenge with Stx1 or Stx2. The observed differences in
pathophysiology elicited by the two toxins may contribute to a
better understanding of the differences in clinical manifesta-
tions produced by the toxins.
MATERIALS AND METHODS
Reagents. Recombinant Stx2 was obtained from BEI Resources (Manassas,
VA). Purified recombinant Stx1 was prepared from cell lysates obtained from
E. coli DH5 harboring plasmid pCKS112, which contains the stx1 operon
under the control of a thermoinducible promoter (45). Stx1 was purified from
cell lysates by sequential ion-exchange and chromatofocusing chromatogra-
phy. The purity of toxins was assessed by SDS-PAGE with silver staining and
by Western blot analysis. Prepared toxins contained 0.1 ng endotoxin per
ml, as determined by Limulus amoebocyte lysate assay (Associates of Cape
Cod, Inc., East Falmouth, MA).
Animals. Papio cynocephalus cynocephalus or P. c. anubis baboons were pur-
chased from the Oklahoma Baboon Research Resource at the University of
Oklahoma Health Sciences Center. All baboons were juvenile (1.5 to 3 years; 6
to 8 kg), before sexual maturation, were outbred and free of tuberculosis, and
had leukocyte concentrations of 15,000/mm3. The animals were housed and
used in accordance with the guidelines and approved protocols of the institu-
tional animal care and use committees and the institutional biosafety committees
of Boston University School of Medicine and the University of Oklahoma Health
Sciences Center.
Toxin challenge procedures. The animal studies were performed at the Uni-
versity of Oklahoma Health Sciences Center animal annex, using previously
published procedures (42, 44). Briefly, baboons were fasted overnight before the
study, with free access to water. They were sedated the morning of the experi-
ment by use of ketamine (10 mg/kg of body weight, given intramuscularly [i.m.])
and were orally intubated. Anesthesia was maintained using sodium pentobar-
bital (5 to 10 mg/kg for maintenance) as deemed necessary by monitoring the
eyelid reflex. An indwelling catheter was placed in the forearm cephalic vein for
bolus infusion of toxin (1 to 2 ml). A second catheter was inserted into the
femoral vein by venous cutdown and secured subcutaneously by an internal
injection cap (Braun), where it remained for the rest of the study period and was
used for blood draws, infusion of saline to replace insensible loss, central venous
pressure (CVP) monitoring, and anesthesia. Death is not an end point for these
studies, and baboons were euthanized according to established criteria if deemed
necessary before the end of the 7-day experimental period. At necropsy, the gross
pathology of the organs was examined and tissues were harvested for archiving.
All animals received enrofloxacin (Baytril; 10 mg/kg i.m.) prior to cutdown and
catheter placement on day 0. Baboons then received either prophylactic levo-
floxacin (Levaquin; 3.5 mg/kg as an intravenous [i.v.] bolus) or enrofloxacin (10
mg/kg i.m.) each day over the experimental period.
Animals were weighed daily, and toxin-induced hypovolemia was controlled
based on criteria developed in previous studies (44). Replacement of fluids with
saline (no more than three bolus infusions of 10 ml/kg) was done according to the
following criteria: (i) if weight is less than that at time zero (T0), then infuse
sufficient normal saline to return animal to initial weight (1 g  1 ml) at 1
ml/kg/min; (ii) if mean arterial pressure is70 mm Hg, then infuse normal saline
(10 ml/kg at 1 ml/kg/min), repeating as needed, while following CVP and mean
systemic arterial pressure (MSAP) and stopping when MSAP is 70 mm Hg, or
sooner if the CVP is10 cm H2O; (iii) if CVP is3 cm H2O, then infuse normal
saline and repeat as needed to raise the CVP to 3 cm H2O; and (iv) if urine
output is2 ml/kg/h, but weight, MSAP, and CVP are not low, then infuse saline
and repeat as needed or until the CVP is 10 cm H2O.
Hematology, clinical chemistry, and urine analyses. Blood samples were
obtained at T0 (before toxin challenge), eight times during the first 24 h, and
daily thereafter. Complete blood counts (CBCs) were determined with a
Horiba ABX Micros 60 hematology analyzer (Horiba, Irvine, CA). Blood
smears were stained with Wright’s stain, and schistocyte counts were deter-
mined as percentages of 200 red blood cells. A Foley catheter (6 French units,
30 cm, 1.5-ml balloon; Rusch, Research Triangle Park, NC) was inserted for
urine collection. The animals were all similar in size (body surface area);
urine was collected on day 0 before toxin challenge for 60 min and on
subsequent days for 20 min. Urinalysis was obtained using dipsticks (Multistix
10SG) on samples collected before saline infusion if indicated to correct for
hypovolemia. Blood urea nitrogen (BUN) and creatinine levels were deter-
mined on citrated plasma by standard clinical chemistry analyses (Veterinary
Associates Laboratory, Edmond, OK). Activated partial thromboplastin
times (APTT) were determined on citrated plasma by use of a KC4 coagu-
lation analyzer (Trinity Biotech, Wickland, Ireland) and TriniCLOT auto-
mated APTT reagent (Trinity Biotech). The APTT tests for all factors in the
intrinsic coagulation pathway, including factors II, V, VIII, IX, X, XI, and
XII, and is independent of platelet counts. Fibrinogen levels were determined
by reference to a standard curve, using a KC4 coagulation analyzer. For the
standard curve, bovine thrombin was added to a reference plasma of known
fibrinogen content, and the clotting time was inversely proportional to the
fibrinogen content. The fibrinogen level at T0 for the 21 animals in this study
was 141.8  40.6 mg/dl (mean  standard deviation [SD]).
Cytokine analyses. Cytokine protein levels were quantified by xMAP mul-
tiplex fluorescent bead-based assays, using a Luminex 200 IS system (Milli-
pore, Billerica, MA), Luminex xPONENT software (Luminex, Austin, TX),
and nonhuman primate cytokine panel kits (Millipore), which provide the
beads, buffers, and detection reagents. Samples were thawed, diluted as
appropriate, and incubated with beads for 2 h at room temperature with
vigorous mixing. Samples were washed twice with vacuum filtration and
incubated with biotin-conjugated antibodies selective for each biomarker for
1 h at room temperature. Phycoerythrin-conjugated streptavidin was added,
and samples were incubated for 30 min at room temperature, followed by
washing. Beads were resuspended in 150 l sheath fluid, and samples were
assayed on a Luminex 200 system. Standard curves for each biomarker ranged
from 0 to 10,000 pg/ml. Samples with values of 9,000 pg/ml were diluted
appropriately and reanalyzed. For each sample, the median fluorescence
intensity was analyzed with a weighted 5-parameter logistic (Milliplex Ana-
lyst; Millipore) and quantified relative to the standard curve for that cytokine.
Differences from baseline values were analyzed by paired Student’s t test, and
P values of 0.05 were considered significant.
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RESULTS
Survival. Anesthetized baboons were challenged with a sin-
gle intravenous bolus injection of recombinant, purified Stx1 or
Stx2 at different doses. Blood was taken just before toxin chal-
lenge (T0), followed by sampling at defined periods thereafter.
Survival after challenge with 10, 50, or 100 ng/kg Stx1 was dose
dependent (Fig. 1A), with the highest dose lethal for all ani-
mals, with mortality by day 2 or 3. All animals challenged with
10 ng/kg Stx1 (n  3) survived. The 50-ng/kg Stx1 dose (n  5)
was more severe, but one animal eventually recovered, and the
100-ng/kg Stx1 dose (n  5) was lethal. Baboons were more
sensitive to Stx2, in that 3 of 4 animals challenged with 10 ng/kg
Stx2 were survivors, but challenge with 50 ng/kg Stx2 (n  4)
was lethal, though mortality was delayed until day 4 or 5 (Fig.
1B). Median survival times at the lethal dose were different
(57.5 h for Stx1 and 121.3 h for Stx2; log rank [Mantel-Cox]
test). The animals died at a much lower dose of Stx2, but the
time to death was longer. For survivors, there were no changes
in symptoms or mortality after this 7-day period. Several sur-
viving baboons were monitored for 28 days, with no persistent
or emerging clinical signs, and appeared to be fully recovered.
Hematology. Complete blood counts performed on blood
samples at each time point showed a progressive loss of circu-
lating platelets after challenge with Stx1 or Stx2 (Fig. 2). The
extent of thrombocytopenia was dose dependent, with recovery
of cell counts if the animal received a low dose or was recov-
ering. Compared to Stx1 challenge, a more gradual develop-
ment of thrombocytopenia with time was observed after Stx2
challenge (Fig. 2A and B). Animals developed anemia after
challenge with either toxin, with a gradual decline in red blood
cell counts (Fig. 2C and D) that was reflected in significant
declines in hematocrit (Table 1). In general, white blood cell
counts did not change (Table 1), with the exception of low-
dose Stx1-challenged animals, who had elevated white cell
counts at 24 and 48 h, probably reflecting an acute-phase
response. Examination of blood smears obtained at euthanasia
or on day 6 or 7 revealed schistocytes (fragmented red blood
cells) in toxin-challenged animals (Table 1). Although platelet
levels declined, consumptive coagulopathy or disseminated in-
travascular coagulation was not evident because APTT were
prolonged modestly only after 24 to 48 h and fibrinogen levels
remained steady for several days, actually increasing during the
acute-phase response (Fig. 3).
Acute renal failure. Renal damage was a consequence of
challenge with either Stx1 or Stx2. Urine output decreased in
both toxin-challenged groups in the first 24 h, essentially ceas-
ing at the high doses (Fig. 4A and B). Proteinuria, indicative of
glomerular damage and a loss of filtration function, was dose
dependent for both toxins but more sensitive to Stx2 (Fig. 4C
and D). Increases in plasma BUN and creatinine by 24 to 48 h
paralleled the onset of kidney damage after challenge with
either toxin (Fig. 5). The levels returned to baseline after
low-dose toxin challenge or if the responses were compensated
and the animal was recovering. Most animals showed physical
signs of edema by 24 to 48 h, with swelling of the face and
abdomen, which resolved within a day or two in the low-dose-
challenged animals. However, despite frequent monitoring and
fluid support to maintain central venous pressure, animals who
received the higher toxin doses had progressive loss of kidney
function and thrombocytopenia leading to death. Gross pa-
thology observations of the kidneys at necropsy on day 2 (48 h)
after challenge with a 100-ng/kg Stx1 lethal dose revealed mild
to moderate congestion at the cortico-medullary junction (Fig.
6B). In contrast, the 50-ng/kg Stx2 lethal dose resulted in
severe medullary congestion and marked cortical ischemia at
necropsy on day 5 (121.6 h) postchallenge (Fig. 6C).
Systemic inflammation. Quantification of circulating proin-
flammatory biomarkers revealed a systemic inflammatory re-
sponse with shared and unique features depending on the toxin
challenge. Interleukin-6 (IL-6) and monocyte chemoattractant
FIG. 1. Baboons are more sensitive to Stx2, but with a delayed time
course. Baboons were challenged with an i.v. bolus of Stx1 (A) or Stx2
(B) in sterile saline, and animals were monitored over a 7-day period.
Animals were challenged with toxin at 10 ng/kg (dotted line), 50 ng/kg
(solid line), or 100 ng/kg (dashed line). A total of 21 animals were
challenged with either Stx1 at the three doses (n  3, 5, and 5) or Stx2
at two doses (n  4 and 4).
FIG. 2. Thrombocytopenia and anemia result after toxin challenge.
Changes in platelet (A and B) and red blood cell (C and D) counts
were determined at the indicated time points after challenge with 10
ng/kg (Œ), 50 ng/kg (f), or 100 ng/kg (F) Stx1 or Stx2. Data shown are
means  SD.
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protein 1 (MCP-1) are global markers of systemic inflamma-
tion that predict outcomes in patients and animal models of
bacterial sepsis (21, 28, 31), and increases were observed in
baboons after challenge with the toxins (Fig. 7A to D). Nota-
bly, different response patterns could be observed between the
two toxins. The early and sustained rise in IL-6 after Stx1
challenge, from 4 to 24 h, was not observed in the Stx2-chal-
lenged baboons, although the sharp rise in IL-6 levels in the
high-dose groups (100 ng/kg Stx1 and 50 ng/kg Stx2) just before
death was a shared response. A significant difference from
baseline IL-6 levels was observed by 30 min after challenge
with 50 or 100 ng/kg Stx1 (P  0.01). At the high Stx1 dose,
elevated IL-6 levels persisted, with differences from baseline at
6 to 8 h (P  0.01) and 10 h (P  0.001). Increases in MCP-1
levels occurred similarly 24 to 48 h after Stx1 or Stx2 challenge,
in a dose-dependent fashion (Fig. 7C and D), although the rise
was more gradual after Stx2 challenge. Granulocyte colony-
stimulating factor (G-CSF) increased within 1 h (P 0.05; P
0.05 after 4 h) after challenge with 100 ng/kg Stx1, with sus-
tained rises over several days with the 50- and 100-ng/kg Stx1
doses. In contrast, little G-CSF was induced after Stx2 chal-
lenge, even with the 50-ng/kg dose that otherwise elicited se-
vere responses in the baboons (Fig. 7E and F). Baboon tumor
necrosis factor alpha (TNF-) was not detected in plasma after
challenge with either toxin (Fig. 7G and H), consistent with
previous observations in the baboon Stx1 model obtained with
a different antibody-based assay (44). There were either no
changes or no detectable levels of granulocyte-macrophage
colony-stimulating factor (GM-CSF), IL-1, IL-2, IL-4, IL-12/
23, IL-13, IL-17, IL-18, gamma interferon (IFN-), and mac-
rophage inflammatory protein 1 (MIP-1).
DISCUSSION
The availability of the baboon Stx1 and Stx2 toxemia models
permits parallel analyses of shared and unique responses elic-
ited by the toxins in a near-human setting. The major obser-
vations from this study are that a single bolus injection of Stx1
or Stx2 induced shared responses of thrombocytopenia, ane-
mia, and acute renal failure in baboons, but there were distinct
TABLE 1. Hematology changes 24 h after toxin challengea
Toxin Dose (ng/kg) Hematocrit (%) WBC count (cells/nl) Schistocytes (%)b
Stx1 10 34.6  3.1 (32.5–38.1)* 17.4  5.5 (12.5–23.3)*** 1.8  0.3 (1.5–2)
50 33.0  3.5 (27–35.4)** 7.7  2.4 (4.5–10.2) 6.3  3.5 (0.5–9)
100 31.3  2.7 (27.6–34.8)*** 6.9  2.8 (4.4–10.5) 3.8  3.0 (1.5–9)
Stx2 10 30.9  0.9 (29.5–31.8)*** 9.2  2.8 (6.8–13.1) 3.1  4.9 (0–10.5)
50 31.0  5.5 (25.3–36.7)** 10.6  2.0 (8.4–10.7) 4.0  1.8 (1.5–5.5)
Nonec 0 38.3  2.9 (33–45) 7.6  2.5 (3.1–11.1) 0.8  0.9 (0–3.0)
a Data are means  SD (ranges). , P  0.05; , P  0.001; , P  0.0001 compared to group prior to challenge (Student’s t test).
b Percentage at euthanasia, or on day 6 or 7 for long-term survivors.
c T0 data before challenge for all animals in the study (n  21).
FIG. 3. Consumptive coagulopathy was not present during the dis-
ease course. The APTT (A and B), which are not dependent on
platelet counts, were steady or modestly prolonged several days after
Stx1 or Stx2 challenge. Fibrinogen levels (C and D) are shown as a
percentage of the T0 value for each animal. The absolute fibrinogen
level at T0 before challenge was 141.8  40.6 mg/dl (n  21). The
symbols for toxin doses are the same as those in Fig. 2. Data shown are
means  SD.
FIG. 4. Progressive loss of renal function after Stx1 or Stx2 chal-
lenge. Urine output (A and B) was measured in all animals, using
samples collected at the indicated time points. Data shown are for
urines collected before saline infusion to correct for hypovolemia, as
defined in Materials and Methods. Proteinuria (C and D) was deter-
mined by dipstick measurements immediately after collection. Data
shown are means  SD.
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differences in the timing and magnitude of responses elicited
by the two toxins. Furthermore, although both toxins induced
a systemic inflammatory response, the cytokine patterns in-
duced were distinct between the toxins, with differences in the
mediators induced as well as in the timing and magnitude of
the responses.
We showed that both toxins alter hematologic parameters
and target the kidneys, with resulting thrombocytopenia, ane-
mia, red blood cell fragmentation, progressive anuria, protein-
uria, and reduced glomerular function. In patients, complete
HUS has been defined as having platelet counts of 150,000/
l, a hematocrit of 30% with evidence of intravascular he-
molysis, and a BUN level of 20 mg/dl, and incomplete HUS
is defined as having two of these criteria (2). The hematologic
and renal function changes observed in the baboons after a
single-dose challenge with Stx1 or Stx2 were similar to those
observed in patients.
Differences in the physiologic responses elicited by the tox-
ins in the baboons were largely in their timing. While the
absolute losses of platelet counts were similar, a high dose of
Stx1 resulted in fairly abrupt thrombocytopenia by 24 to 48 h,
whereas the loss of platelets after Stx2 challenge was through
a gradual daily decrease until either euthanasia at day 4 or 5 or
resolution and recovery. Differences in renal gross pathology
may also be attributable to the timing of organ injury. In the
kidney, the cortico-medullary congestion noted on day 2 after
high-dose Stx1 challenge may progress to the severe medullary
congestion seen on day 5 after Stx2 challenge. While it is
possible that the far more severe renal lesions after high-dose
FIG. 5. Acute renal failure occurs after challenge with either toxin
but is delayed by 2 to 3 days after Stx2 challenge. BUN (A and B) and
creatinine (C and D) levels were determined in citrated plasma sam-
ples taken at the indicated time points. The symbols for toxin doses are
the same as those in Fig. 2. Data shown are means  SD.
FIG. 6. Kidney gross pathology observations at necropsy. The or-
gan appearance of a kidney from an unchallenged baboon of approx-
imately the same age (A) is compared with those from a baboon
euthanized 48 h after challenge with 50 ng/kg Stx1 (B) and a baboon
euthanized 121.6 h after challenge with 100 ng/kg Stx2 (C). Both
toxin-challenged animals had acute renal failure, as judged by reduced
urine output and proteinurea and increased plasma BUN and creati-
nine levels. The gross pathology differences between Stx1 and Stx2
shown are representative of all animals in the high-dose (100 ng/kg
Stx1 and 50 ng/kg Stx2) groups.
FIG. 7. Stx1 and Stx2 challenges result in distinct inflammatory
response patterns. Biomarkers were measured in citrated plasma sam-
ples after challenge with 10 ng/kg (Œ), 50 ng/kg (f), or 100 ng/kg (F;
Stx1 only) toxin, using a multiplex bead-based assay designed for quan-
tification of nonhuman primate antigens. Dose-dependent changes in
the proinflammatory mediators IL-6 (A and B), MCP-1 (C and D), and
G-CSF (E and F) are shown as means  SD. (G and H) Neither toxin
stimulated production of circulating TNF-. Paired t tests were used to
determine statistical differences from baseline for the following early
biomarker changes: IL-6 at 100 ng/kg Stx1 (P  0.01 at 0.5, 2, 6, and
8 h; P 0.05 at 4 h; and P 0.001 at 10 h) and 50 ng/kg Stx1 (P 0.01
at 0.5 h and P  0.05 at 4, 6, 8, and 10 h) and G-CSF at 100 ng/kg Stx1
(P  0.05 at 4, 6, 8, and 10 h).
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Stx2 challenge represent toxin specificity, it is also possible that
the additional 2 to 3 days to euthanasia and necropsy allowed
more time for the pathology to develop. It is notable that
anemia developed after exposure to either toxin, and red cell
counts continued to decrease and remained low even when
markers of renal function and inflammation were resolving
after low-dose toxin challenge and the animal appeared to be
recovering. Patients with STEC-induced HUS can become
profoundly anemic and require transfusions (16).
The shorter, 2- to 3-day survival time with a lethal dose of
Stx1 (100 ng/kg; median time to death, 57.5 h) than the 4- to
5-day survival time after a lethal dose of Stx2 (50 ng/kg; median
time to death, 121.3 h) demonstrated a higher sensitivity to
Stx2 but a longer time to severe organ injury and death. More-
rapid kidney injury by Stx1 is supported by the observations
that BUN and creatinine levels increased more acutely and
urine output dropped more rapidly and to a greater degree in
the Stx1-challenged animals. We do not interpret this to mean
that Stx1 preferentially targets the kidney, but rather that there
may be differences in toxin dissemination or processing in vivo
that could contribute to delayed Stx2 renal injury. The molec-
ular basis for delayed organ damage and mortality after Stx2
remains enigmatic, because both toxins require the Gb3
(CD77) receptor for cell intoxication (27), although they bind
with slightly different kinetics and affinities (17, 24). Using the
gnotobiotic piglet model and isogenic E. coli strains with sim-
ilar toxin production capabilities, Donohue-Rolfe et al. showed
that oral challenge with strains expressing Stx2 alone induced
more neurologic symptoms than did challenge with strains that
express only Stx1 (6, 37). This also supports the notion that the
toxins can induce different systemic pathophysiologies. With
respect to timing differences, the current experimental baboon
observations are reminiscent of clinical observations in which
renal injury in young children correlates with Stx2 production
from STEC and the development of hemolytic-uremic syn-
drome is delayed by an average of 6 days after infection (2).
Measurement of circulating biomarkers by bead-based mul-
tiplex assays revealed unexpected differences in the proinflam-
matory cytokines induced by Stx1 and Stx2, with differences in
the mediator induced as well as in the timing and magnitude of
the response. From a broad perspective, Stx1 appeared to
induce a stronger systemic inflammatory response in the ba-
boons, as judged by more cytokines being induced, and at
higher levels. Though they are present in the circulation, a role
for these mediators in disease severity, outcome, or prognosis
cannot be inferred from the current study. An inflammatory
response is well documented for pediatric patients with STEC
infection, who have elevated IL-6, IL-10, IL-1Ra, G-CSF, and
chemokine levels (29, 30) and may (23) or may not (30) have
elevated plasma TNF- levels. In the baboons, IL-6 and
MCP-1 levels were induced to similar levels after either toxin
and were dose dependent, but Stx2-induced responses were
more gradual and were delayed by several days. In contrast,
changes in G-CSF were very different between the toxins. Stx1
challenge increased circulating G-CSF levels, particularly at
the 50- and 100-ng/kg doses, whereas G-CSF was only mini-
mally increased early after Stx2 challenge, regardless of the
toxin dose. To our knowledge, Stx toxin-specific changes in
plasma cytokines have not been studied in parallel in other
animal models, and the baboon data suggest that the toxins
may exert independent influences on cytokine mRNA stability
and/or gene transcription in susceptible cells. Increased G-CSF
levels would be expected to result in increased white cell
counts, but this did not occur, nor did differential cell counts
change (not shown). In fact, the animals challenged with 10
ng/kg Stx1 paradoxically had the highest white cell counts and
the lowest plasma G-CSF levels. G-CSF production is tightly
regulated at both the translational and posttranslational levels,
and stabilization of mRNA is observed as a result of multiple
mediators, including IL-4, TNF-, and IFN- (1). However,
these mediators were not observed in the baboons, at least not
systemically. In mice, Stx1 localizes to the bone marrow of the
spine, long bones, and ribs (34), and it is possible that even
though peripheral cells may produce G-CSF, its biological ac-
tivity at the bone marrow may be inefficient or blocked. The
distribution of toxins in patients or nonhuman primates is not
known, and studies are in progress to understand the molecu-
lar basis and biologic significance of the cytokine responses
unique to each toxin.
We did not detect plasma TNF- in any of the baboons after
challenge with either toxin, even at high doses, consistent with
previous Stx1 studies of the baboon model (40, 44). TNF- is
a well-known early proinflammatory mediator of bacterial sep-
sis in patients and most animal models, including baboons (13,
26, 42). In contrast, mice have elevated plasma TNF- and
kidney TNF- mRNA after multiple Stx2 injections that in-
duce thrombocytopenia and renal injury (36), and cultured
cells will undergo TNF- transcription and protein release
after Stx1 intoxication under lipopolysaccharide (LPS)-free
conditions (35). These differences may be species dependent,
or TNF- production may rely on a balance of gene transcrip-
tion induced by other local mediators despite toxin-induced
pressures to undergo cellular apoptosis (22, 41).
While there are parallels between the current baboon results
and patient observations, the current study models are most
accurately viewed as nonhuman primate models of toxemia,
not STEC infection, where the pathogen is bacterial and the
infection route is gastrointestinal. Furthermore, the toxins
were administered as a bolus challenge rather than as repeated
or intermittent toxin exposures, as would be expected during
an intestinal bacterial infection. We observed increased white
cell counts only after low-dose Stx1 challenge, whereas in pa-
tients with STEC infection, a white cell count of 10,500/l is
associated with a 5-fold-increased risk of HUS (2). It is rea-
sonable to expect that patients infected with STEC will be
exposed to a variety of bacterial factors and that possible
breaching of the gut epithelial barrier due to injury will exac-
erbate the insult, providing exposure to LPS from commensal
flora. In an earlier baboon Stx1 study, LPS and Stx1 coadmin-
istration resulted in more-severe kidney damage in response to
an otherwise subtoxic challenge (39). This is underscored by
studies which demonstrated the importance of other bacterial
molecules necessary for epithelial attachment in the gut and
the interplay between the toxins, bacterial colonization, and
inflammation that give rise to systemic disease (3, 32).
Ongoing studies in our laboratory continue to characterize
the baboon toxemia models with respect to inflammation, pa-
thology, and neurologic abnormalities to further advance our
understanding of how the toxins exert their influence at the
organ and cellular levels. The current nonhuman primate mod-
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els of Stx1 and Stx2 toxemia provide a platform for reproduc-
ible testing of immunotherapeutics and antitoxin compounds
in a near-human setting, with definable outcomes that have
clinical meaning. With the baboon models, it should be possi-
ble to test therapeutics tailored to one or both toxins and to
independently judge effects on toxin-specific responses. In this
way, it may be possible to more rapidly develop and advance
therapeutics for STEC infection for a clinical setting in which
patients may present with STEC strains that secrete different
ratios of toxins.
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